Journal of Ayurveda and Integrative Medicine (Nov 2023)

Evaluating Ayurvedic mouthwash and soda-salt mouthwash for oral mucositis in head and neck cancer: A randomized controlled trial

  • CK Saniya,
  • Mangalagowri V. Rao,
  • Rajkala Patil,
  • Sunil Choudhary,
  • Om Prakash Singh,
  • K.S. Dhiman

Journal volume & issue
Vol. 14, no. 6
p. 100829

Abstract

Read online

Background: Patients undergoing radiotherapy (RT) or concurrent chemo-radiation (CCRT) for head and neck squamous cell carcinoma (HNSCC) often suffer from side effects such as mucositis, xerostomia, pharyngitis, laryngitis, and pain, which are being managed symptomatically by alcohol-based mouthwashes. Objectives: To determine the effectiveness of Ayurvedic mouthwash “Draksha Guduchyadi Kashaya” in reducing the severity of oral side effects of chemo-radiation. Material and methods: This concurrent parallel randomized controlled study was conducted at Sir Sunderlal Hospital, BHU, on 70 HNSCC patients scheduled to undergo RT/CCRT. Patients who met the inclusion-exclusion criteria were enrolled, and 35 were randomly assigned to either the intervention group (Ayurveda) or the control group using a simple random technique (lottery method). Blinding was not implemented in this study. Patients in the intervention group (Ayurveda) were instructed to perform kavala with 50 ml of “Draksha Guduchyadi Kashaya” for 2 min, ten times daily, while the control group performed 2-min gargling with soda-salt mouthwash ten times daily. Results: Out of the 70 patients enrolled, data from 60 patients were analyzed, revealing statistically significant differences in the onset of mucositis (p = 0.049), pharyngitis (p = 0.034), laryngitis (p = 0.009) and intensity of variables such as mucositis (p = 0.000), xerostomia (p = 0.046), pharyngitis (p = 0.002), laryngitis (p = 0.035), and pain (p = 0.000). These findings indicate that Ayurvedic mouthwash may be beneficial in managing the oral side effects of chemo-radiation in HNSCC. Conclusion: This AYUSH financially supported trial (Reg No: CTRI/2020/04/024672) demonstrates promise as a safe and cost-effective alternative for managing oral complications of RT/CCRT, offering complementary treatment for comprehensive cancer care.

Keywords